Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07726888 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date: Aug 1, 2026 to Jul 31, 2026
    • Site details revised
    v3
  2. Secondary endpoints: details revised at 3 of 11 entries
    • Study title shortened, about 4 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In a real-world setting, this study systematically evaluates the clinical efficacy and safety of guselkumab (GUS) in the treatment of ulcerative colitis (UC), encompassing multi-dimensional outcomes including clinical remission, biochemical remission, endoscopic remission, histologic healing, and intestinal ultrasound changes.
Trial Details
NCT Number NCT07726888
Lead Sponsor Second Affiliated Hospital of Wenzhou Medical University
Collaborators: Xian-Janssen Pharmaceutical Ltd.
Conditions
(from sponsor)		 Ulcerative Colitis (Disorder), Guselkumab
Related terms Colitis, Ulcerative
Enrollment 97 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov